Title
American Society of Clinical Oncology 2011 Annual Meeting Update: Summary of Selected Gynecologic Cancer Abstracts

Permalink
https://escholarship.org/uc/item/5bz1d5ng

Journal
Gynecologic Oncology, 122(2)

ISSN
0090-8258

Authors
Tewari, Krishnansu S
Monk, Bradley J

Publication Date
2011-08-01

DOI
10.1016/j.ygyno.2011.06.028

Copyright Information
This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed
Meeting Report

American Society of Clinical Oncology 2011 Annual Meeting Update: Summary of Selected Gynecologic Cancer Abstracts

Introduction

The 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, June 3–7, 2011 and focused on “Patients, Pathways, Progress”. 40,000 cancer specialists from around the world gathered to discuss the latest innovations in research, quality, practice, and technology. Over 100 studies in gynecologic cancer were presented, including novel therapeutic approaches in not only ovarian cancer, but also in endometrial and cervical cancers. This report will highlight phase III randomized trials in ovarian cancer and other selected studies.

Phase II trials in locally advanced and metastatic/recurrent cervical cancer

Several studies examined the efficacy and tolerability of combining anti-EGF-based therapy to chemoradiation and gene therapy to reconstitute wild type p53 function for locally advanced cervical carcinoma (Table 1). Erlotinib, a tyrosine kinase EGFR inhibitor, yielded no objective responses when studied previously by the GOG in women with recurrent disease. However, Rodrigues et al. combined erlotinib 150 mg/d with chemoradiation plus brachytherapy and reported a 94.4% CR, with 3-yr OS 80%, and grade 3/4 skin rash in 13%. Two additional phase II trials in locally advanced tumors studied weekly intra-tumoral recombinant adenoviral human p53 (rAd-p53) gene therapy in conjunction with pelvic radiation. In a randomized phase II trial, the overall response rate (ORR) of pelvic RT with and without gene therapy (1–4 × 10^{12} rAD-p53 viral particles × 6 weeks) was 100% vs 72.2%, respectively (p=0.0149). Anticipated side effects reported in both studies included transient fever. For metastatic disease, the second generation platinum doublet nedaplatin plus paclitaxel was associated with an objective RR of 42.2%.

Phase II trials of mammalian target of rapamycin inhibitors (mTORi) in endometrial cancer

Loss of phosphatase and tensin homolog (PTEN) protein function occurs in 26–83% of endometrial carcinomas leading to deregulation of the PI3K/AKT/mTOR signaling. Four phase II studies evaluated the response, survival and toxicity in advanced and recurrent disease (Table 2). Two randomized phase II trials studied mTORi(s) versus hormonal therapy. In one study, patients with unresectable disease were randomized to oral ridafarolimus 40 mg for 5 days/week versus medroxyprogesterone 200 mg/d or megestrol 60 mg/d. Interim analysis of the first 114 patients treated demonstrated a median PFS of 36 mos for ridafarolimus and 1.9 mos for progestin therapy (HR 0.53, p=0.008) with grade 3/4 AEs of hyperglycemia (19%) and anemia (9%). The second study (intravenous tensirolimus vs tensirolimus plus megestrol acetate alternating with tamoxifen) was closed due to an unacceptable rate of venous thromboses in the combined regimen. A non-randomized phase II study of daily everolimus plus letrozole was associated with an objective RR of 21%.

Phase II trials of anti-angiogenesis agents in ovarian cancer

Agents that target the angiogenic pathway continue to generate interest in ovarian cancer (Table 3). Simultaneous targeting of the MET and VEGF signaling pathways with cabozantinib was reported for recurrent disease. Randomization was halted and patients were unblinded based on an observed high rate of clinical activity, including an ORR 24%. In two non-randomized phase II trials, bevacizumab was studied with pegylated liposomal doxorubicin (PLD) plus carboplatin (PLD 30 mg/m^2 and carboplatin (AUC5) day 1 plus bevacizumab 10 mg/kg on days 1 and 15 every 28 days) in platinum sensitive disease and with the VEGFR2/Raf kinase inhibitor, sorafenib, in bevacizumab-naïve patients with recurrence (sorafenib 200 mg twice daily with bevacizumab 5 mg/kg every 2 weeks every 28 days). In the former trial the ORR was 72.2% with a median PFS of 14 mos. Thirty-nine patients (72.2%) discontinued therapy due to an adverse event. In the latter study, 24% PR lasting a median 15.5 mos was noted with hypertension (47%) and thrombosis (13%) among the AEs. The combination of docetaxel plus aflibercept for recurrence resulted in an ORR of 54% (77% PltS, 45% PltR; 10 CRs; PFS 6.2 mos, OS 24.3 mos). Neutropenia (72%), fatigue (50%) and dyspnea (22%) represented grade 3/4 toxicities.

Phase II trials of poly(ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer

Olaparib is an oral PARPi that is active in high grade serous ovarian cancer with and without BRCA1 and BRCA2 mutations (Table 3). Maintenance olaparib (400 mg twice daily) was studied in a randomized placebo-controlled phase II trial in platinum sensitive...
patients in sustained partial or complete response. When the pre-
determined 153 progression events (58%) had occurred, PFS was 
significantly longer in the olaparib than placebo group (HR 0.35).

Despite promising phase II data indicating efficacy and tolerability 
of the intravenous PARPi, iniparib, in triple-negative breast cancer 
(TNBC), the phase III registration trial ground to a halt when it was 
reported at this year’s meeting that the combination of iniparib plus 
carboplatin and gemcitabine failed to meet its co-primary endpoints 
of PFS and OS in TNBC. In two non-randomized phase II studies of the 
inhaled PARPi, iniparib, in triple-negative breast cancer 
(Table 3). In the platinum resistant population, the 
median PFS was 5.9 mos.

**Phase II trials of other novel agents in ovarian cancer**

The PRECEDENT trial was an international, open-label, random-
ized phase II study comparing pegylated liposomal doxorubicin 
(PLD) plus the folic acid/desacetylvinblastine hydrazide conjugate, 
EC145, to PLD alone in women with platinum resistant disease 
(Table 3). Patients were randomized 2:1 to PLD (50 mg/m² IV q 
28 days) with and without EC145 (2.5 mg IV weeks 1 and 3). Folic 
receptor (FR) status was determined prior to randomization using 
technetium labeled EC20, an FR targeted imaging agent. In the 
intent-to-treat population of patients with measureable disease, 
EC145 plus PLD was found to be the first combination to show a 
statistically significant impact on PFS over standard therapy in 
women with platinum resistant disease (HR 0.626). For patients 
with 100% EC20 positive tumors, the PFS was 24.0 wks (investiga-
tional arm) and 6.6 wks (control) (HR 0.381). A phase III 
randomized trial is pending activation.

The hypomethylating agent, decitabine, was used with carbop-
latin to reverse acquired platinum resistance (Table 3). The ORR 
was 35% and included 1 CR and 5 PRs (median PFS 309 days). Grade 
3/4 hematologic AEs in all principal cell lineages occurred in 11– 
23%. Demethylation of ovarian cancer-associated genes, MLH1, 
RASSF1a, HOXA10, and HOXA11 in tumors from day 1 to day 
23% positively correlated with PFS (p<0.05). This trial constitutes the 
first-in-class proof of concept that epigenetic intervention can 
restore platinum sensitivity in ovarian cancer.

<table>
<thead>
<tr>
<th>Type of trial</th>
<th>Abs #</th>
<th>Agents/dose</th>
<th>Mechanism</th>
<th>Type of patients</th>
<th>Results</th>
<th>HR</th>
<th>P Value</th>
<th>Major toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized phase II</td>
<td>5097 Weekly intra-tumor</td>
<td>rAd-p53 plus pelvic</td>
<td>Gene therapy</td>
<td>Locally advanced cervix (III–IVA)</td>
<td>ORR 100 v 72.2%*</td>
<td>CR 52.4% v 44.4%</td>
<td>*P = 0.01 Feve</td>
<td></td>
</tr>
<tr>
<td>Phase II combinations</td>
<td>5033</td>
<td>Erlotinib plus CDDP and pelvic RT</td>
<td>Oral TKI (EGFR);</td>
<td>Locally advanced SCCA cervix (III–IBB)</td>
<td>94.4% CR</td>
<td>5.6% PR</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>and pelvic RT followed by RHBPLND vs BT (non-randomized)</td>
<td>cytotoxic</td>
<td></td>
<td></td>
<td>PFS 73.8% at 36 mos</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5038 IFX-Mesna plus carboplatin and pelvic RT followed by RHBPLND vs BT (non-randomized)</td>
<td>Cytotoxic, “down-staging” to assess operability</td>
<td>Locally advanced cervix (III, IIIb)</td>
<td>ORR 89.7%</td>
<td>CR 35.9%</td>
<td>PR 53.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5102 Paclitaxel plus nedaplatin</td>
<td>Second generation platinum doublet</td>
<td>Metastatic/recurrent cervix</td>
<td>ORR 42.2%</td>
<td>CR 22%</td>
<td>PR 16%</td>
<td>26.7% SD</td>
<td></td>
</tr>
<tr>
<td>Phase II single agents</td>
<td>5096 Weekly intra-tumor</td>
<td>rAd-p53 plus pelvic RT</td>
<td>Gene therapy</td>
<td>Locally advanced cervix (III, IIIb)</td>
<td>100% CR</td>
<td>5YS 85.7%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 1**

Novel drugs and treatment strategies for locally advanced and recurrent cervical carcinoma.

<table>
<thead>
<tr>
<th>Type of trial</th>
<th>Abs #</th>
<th>Agents/dose</th>
<th>Mechanism</th>
<th>Type of patients</th>
<th>Results</th>
<th>HR</th>
<th>P Value</th>
<th>Major toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized phase II</td>
<td>5009 Daily ridaforolimus vs progestin or chemOrs</td>
<td>mTORi</td>
<td>Advanced/metastatic endometrium</td>
<td>PFS: 3.6 vs 1.9 mos</td>
<td>HR = 0.53</td>
<td>P = 0.008</td>
<td>An, h, d, s, back pain, anemia, d, F, n, s, h, hypertriglyceridemia, Objective RR 21%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5014 Tensirolimus vs tensirolimus plus megestrol acetate alternating with tamoxifen</td>
<td>mTORi, Progestin- and estrogen-based therapy</td>
<td>Advanced/recurrent endometrium</td>
<td>At least 4 responses (single agent tensirolimus, 2nd stage</td>
<td>–</td>
<td>–</td>
<td>Combined regimen closed due to unacceptable rate of venous thrombosis</td>
<td></td>
</tr>
<tr>
<td>Phase II combinations</td>
<td>5012 Daily everolimus plus letrozole</td>
<td>mTORi, aromatase inhibition</td>
<td>Recurrent endometrium</td>
<td>CBR 42%</td>
<td>Objective RR 21%</td>
<td>PR 7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase II single agents</td>
<td>5013 Daily ridaforolimus</td>
<td>mTORi</td>
<td>Recurrent endometrium</td>
<td>–</td>
<td>–</td>
<td>F, n, s, h, hypertriglyceridemia, Mucositis, f, n, d, anoesthesia, taste alteration, rash</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2**

Phase II trials of mammalian target of rapamycin inhibitors (mTORi) in endometrial carcinoma.

mTORi = mammalian target of rapamycin inhibitor, n = nausea, f = fatigue, An = anemia, d = diarrhea, h = hyperglycemia, s = stomatitis.
Eribulin mesylate is a tubulin inhibitor distinct from taxanes. It suppresses microtubule growth without affecting depolymerization, resulting in sequestration of tubulin into non-functional aggregates. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenously on days 1 and 8 every 21 days. A platinum sensitive population was treated with eribulin 1.4 mg/m² intravenous
HR = .987, P = .87) despite a statistically significant difference in PFS presented at ASCO 2009. However, the use of trabectedin and PLD prolonged survival compared to PLD alone in treating patients second line (adjusted HR = 0.82; 95% CI: 0.69,0.98, P = 0.0285). The largest difference in survival was seen in the subset of women who recurred 6–12 months after front-line platinum based therapy.

Finally, in a disappointing placebo controlled maintenance trial of abagovomab, a murine monoclonal anti-idiotypic antibody directed against CA125, there was no difference in the primary endpoint of PFS among 888 enrolled subjects (P = 0.675) (Abstract LBA 5002).

Translational science in ovarian cancer

Gourley et al. studied microarray expression analysis in 363 formalin-fixed paraffin embedded epithelial ovarian cancer tissues with linked prospectively collected clinical data (Abstract 5000). The resulting molecular taxonomy contains clusters with differing survival with a serous subgroup defined by upregulation of multiple angiogenesis genes. A pro-angiogenic signature may explain the observed response and positive impact on PFS attributed to bevacizumab in GOG 218, ICON7, and most recently, OCEANS.

Lonning et al. analyzed WBC DNA from 899 ovarian cancer patients for BRCA1 promoter methylation and found a significantly increased risk of ovarian cancer in the cohort of patients with blood samples drawn at the time of (OR 4.765; CI 2.814–8.069) or prior to (OR 2.937; CI 1.476–5.845) diagnosis (Abstract 5029). The clinical implications suggest a potential role for hypomethylation of agents, such as decitabine (Table 5), to restore wild-type gene function in patients at established genetic risk.

Human epididymis protein 4 (HE4) is the product of the WFDC2 (HE4) gene and is overexpressed in patients with ovarian carcinoma. Marinaccio et al. investigated the ability of HE4 to predict survival in 35 women with ovarian cancer (stage III, n = 28; stage 4, n = 7) (Abstract 5081). All patients with a HE4 >400 pM died within 2 years of diagnosis, while those with a reduced HE4 at both baseline and 3 months had the best overall survival.

Brief update

Alifrangis et al. from Charing Cross noted that OS for GTN following EMA/CO has improved significantly from 87% to 98%, partly due to the introduction of 2 cycles of low dose EP-induction chemotherapy (etoposide 100 mg/m² and cisplatin 20 mg/m² on days 1 and 2, repeated weekly x 2) before commencing EMA/CO (Abstract 5024). EP-induction given to high risk patients (FIGO score >8 and >6 metastases) was felt to minimize the risk of early deaths.

Conclusion

There are now three phase III randomized studies demonstrating a positive impact in PFS among women with advanced ovarian cancer who receive the anti-angiogenesis drug, bevacizumab. The latest study, OCEANS, demonstrated a 4-month improvement in PFS for women with essentially incurable platinum sensitive recurrent disease. The interim OS analysis from ICON 7 demonstrates improved survival associated with bevacizumab for frontline/maintenance treatment in a high risk subset, and the IRC of GOG 218 was consistent with the investigator’s assessment of response. The non-platinum chemotherapy doublet of PLD plus trabectedin can prolong survival. Based on recent phase II trials, PARPi(s) and mTORi(s) are emerging as drugs of interest in treating ovarian and endometrial cancer, respectively. Finally, the search for novel therapies for women with metastatic/recurrent cervical carcinoma continues.

Conflict of interest statement

Dr. Bradley Monk discloses that he has received research grants from GlaxoSmithKline, PharmaMar, Sanofi-Aventis, Merck and Novartis along with honoraria for speaker bureaus from GlaxoSmithKline, Roche and Johnson and Johnson. Additionally Dr. Monk has been a consultant for Qiagen, Roche, GlaxoSmithKline and Merck. Dr. Krishnansu Tewari discloses that he has received research grants from Precision Therapeutics, Amgen, Imclone, and Biogen Idec and honoraria for speakers bureaus from Genzyme, Vermillion, Qiagen, and Merck.

Krishnansu S. Tewari
The Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, USA

Bradley J. Monk
The Division of Gynecologic Oncology, Creighton University School of Medicine at St Joseph’s Hospital and Medical Center, Phoenix, AZ, USA

Corresponding author at: The Division of Gynecologic Oncology, Creighton University School of Medicine at St Joseph’s Hospital and Medical Center, A Member of Catholic Healthcare West, 500 W. Thomas Road, Suite 800x, Phoenix, AZ 85013, USA.
E-mail address: Bradley.monk@chw.edu.

10 February 2011